Log In
BCIQ
Print this Print this
 

ASN-004

  Manage Alerts
Collapse Summary General Information
Company Ascend Biopharmaceuticals Ltd.
DescriptionVaccine that delivers cancer antigens to dendritic cells which activates immune response to selectively destroy cancer cells which express the polymorphic epithelial mucin (PEM; MUC-1) protein
Molecular Target Polymorphic epithelial mucin (PEM) (MUC-1)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat metastatic breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today